Published Date: 26 Apr 2023
Many women may be wondering what this means for them in light of the Supreme Court's decision on Friday regarding a crucial medication used in medical abortions.
Read Full NewsResearchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.
Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.
For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.
Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.
1.
Nuclear missile workers are contracting cancer: They blame the bases
2.
Novel Agent for Chronic GVHD Wins FDA Approval
3.
MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC
4.
Access to GLP-1 medications associated with a lower risk of colorectal cancer in people with type 2 diabetes: JAMA.
5.
Radiation therapy can promote amphiregulin, which increases growth of metastases
1.
The Transformative Power of Genomics in the Diagnosis and Management of Rare Cancers
2.
Minimal Residual Disease Monitoring: Advances, Clinical Relevance, and Guideline-Based Perspectives
3.
New Hope for Rectal Cancer Patients: Breakthrough Drug Shows Promising Results
4.
The Benefits and Risks of Thrombolytics: A Comprehensive Guide
5.
Liquid Biopsy in Oncology: Innovations in Cancer Detection, Monitoring, and Clinical Use
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
International Lung Cancer Congress®
3.
Genito-Urinary Oncology Summit 2026
4.
Future NRG Oncology Meeting
5.
ISMB 2026 (Intelligent Systems for Molecular Biology)
1.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
2.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
5.
Efficient Management of First line ALK-rearranged NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation